|1.||Lialina, I K: 2 articles (09/2009 - 01/2009)|
|2.||Rasnetsov, L D: 2 articles (09/2009 - 01/2009)|
|3.||Lobach, O A: 1 article (09/2009)|
|4.||Kalnina, L B: 1 article (09/2009)|
|5.||Chataeva, M S: 1 article (09/2009)|
|6.||Nosik, D N: 1 article (09/2009)|
|7.||Kondrashina, N G: 1 article (01/2009)|
|8.||Grigor'eva, A Iu: 1 article (01/2009)|
|9.||Nosik, N N: 1 article (01/2009)|
01/01/2009 - "Fullevir was found to protect tissue culture cells from the cytodestructive action of herpes simplex virus type 1. It was estimated that ED50 = 5.3 microg/ml and ED90 = 29.1 microg/ml. The agent was most effective when it was administered before and 30 minutes after cell culture infection. "
09/01/2009 - "The 90% effective concentration (EF90) was 5 microg/ml. The 50% average toxic concentration was 400 microg/ml. Testing of different (preventive and therapeutic) Fullevir dosage regimens has shown that the drug is effective when used both an hour before and an hour after infection and when administered simultaneously with cell infection. "
|2.||Herpes Simplex Encephalitis (Herpes Encephalitis)
01/01/2009 - "The in vivo study established that Fullevir showed a significant protective effect in experimental herpetic encephalitis. "
01/01/2009 - "as Fullevir) were studied in in vitro (in sensitive cell cultures) and in vivo (on a murine model of experimental herpetic encephalitis) experiments. "
|3.||HIV Infections (HIV Infection)